

GenCore version 5.1.6
Copyright (c) 1993 - 2004 Compugen Ltd.

OM protein - protein search, using SW model

Run on: March 26, 2004, 01:42:25 ; Search time 137 Seconds

(without alignments)
1492.378 Million cell updates/sec

Title: US-09-805-020-72

Perfect score: 3506

Sequence: 1 MSPFRLGLSNFDCGSCQSC.....LVSLFLVSNLVANNDDY 648

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 1017041 seqs, 315518202 residues

Total number of hits satisfying chosen parameters: 1017041

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :
1: SP archaea:*
2: SP bacteria:*
3: SP fungi:*
4: SP human:*
5: SP_invertebrate:*
6: SP_mammal:*
7: SP_mnc:*
8: SP_organelle:*
9: SP_plant:*
10: SP_plant:*
11: SP_todent:*
12: SP_virus:*
13: SP_vertebrate:*
14: SP_unclassified:*
15: SP_virus:*
16: SP_bacteriopl:*
17: SP_archaeopl:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	2844	81.1	571	11	Q8CAV6
2	2293	65.4	469	11	Q8C3L7
3	2120	60.5	683	13	Q7SZH8
4	2100	59.9	683	13	Q7SZH7
5	2045.5	58.3	676	4	Q6EXI6
6	2018.5	57.6	684	13	Q7ZUC5
7	1757	50.1	464	11	Q8ZUC5
8	1566.5	44.7	487	11	Q8ZUC5
9	1491	42.5	724	5	Q61225
10	1447	41.3	763	5	Q6XKX6
11	1345	38.4	754	5	Q6XKX6
12	1290.5	36.8	707	5	Q2Q953
13	1247.5	35.6	683	11	Q6XKX6
14	1241.5	35.4	683	11	Q6XKX6
15	1235	35.2	661	5	Q01669
16	1166.5	33.3	670	13	Q7SY24

17	1160	33.1	670	13	Q8UFZ9	Q81fz9 fuqu rubrip
18	1145	32.7	756	5	Q61224	Q61224 scypha raph
19	1144.5	32.6	680	5	P90980	P90980 caenorhabdi
20	1144.5	32.6	680	5	Q8M088	Q8M088 caenorhabdi
21	1144.5	32.6	682	5	Q8M087	Q8M087 caenorhabdi
22	1144.5	32.6	682	5	P90981	P90981 caenorhabdi
23	1144.5	32.6	936	5	Q19024	Q19024 caenorhabdi
24	1129	32.2	668	13	Q7ZUC5	Q7ZUC5 brachydantio
25	1097	31.3	670	5	Q01715	Q01715 hydra atten
26	1076.5	30.7	674	5	Q01716	Q01716 hydra atten
27	1070.5	30.5	554	5	Q95778	Q95778 drosophila
28	1067	30.4	673	5	Q62567	Q62567 suberites d
29	998	28.5	677	5	Q96397	Q96397 geodia cydo
30	975	27.8	685	5	Q76850	Q76850 calliphora
31	949.5	27.1	1035	5	Q862V2	Q862V2 pichia past
32	892	25.4	1161	3	Q8J213	Q8J213 kluyveromyc
33	885	25.2	1157	3	Q9HP10	Q9HP10 blumeria gr
34	883	25.2	1194	3	Q9Y792	Q9Y792 sporothrix
35	871.5	24.9	1170	3	Q9UYJ5	Q9UYJ5 botrytis cl
36	860.5	24.5	1185	3	Q873Y9	Q873Y9 leptosphaer
37	857	24.4	1136	3	Q9HGK8	Q9HGK8 tuber borch
38	853	24.3	1182	3	Q9Y7C1	Q9Y7C1 magnaporthe
39	850	24.2	697	5	Q96942	Q96942 rhabdocalyp
40	848.5	24.2	447	5	Q86M17	Q86M17 branchiosto
41	845	24.1	991	3	Q96VFE	Q96VFE tuber magna
42	775	22.1	442	13	Q801L5	Q801L5 scyliorhinu
43	739.5	21.1	606	5	Q9V782	Q9V782 drosophila
44	739.5	21.1	606	5	Q9G5Z3	Q9G5Z3 drosophila
45	739.5	21.1	606	5	Q8MT38	Q8MT38 drosophila

ALIGNMENTS

RESULT 1

Q8CAV6 PRELIMINARY; PRT; 571 AA.
AC Q8CAV6;
DT 01-MAR-2003 (TrEMBLrel. 23, Created)
DT 01-MAR-2003 (TrEMBLrel. 23, Last sequence update)
DT 01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
DE Protein Kinase C.
GN A130035A12RIK.
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Mus.
OX NCBI_TaxID=10090;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=C57BL/6J; TISSUE=Thymus;
RX MEDLINE=22354683; PubMed=12466851;
RA The FANTOM Consortium.
RA the RIKEN Genome Exploration Research Group Phase I & II Team.
RT "Analysis of the mouse transcriptome based on functional annotation of
RT 60,770 full-length cDNAs."
RL Nature 420:563-573 (2002).
DR EMBL; AK037664; BAC29843.1; -
DR MGD; MGI:2442369; A130035A12RIK.
DR GO; GO:0005524; P:ATP binding; IEA.
DR GO; GO:0005489; P:electron transporter activity; IEA.
DR GO; GO:0004674; P:protein serine/threonine kinase activity; IEA.
DR GO; GO:0004713; P:protein-tyrosine kinase activity; IEA.
DR GO; GO:0006118; P:electron transport; IEA.
DR GO; GO:0007442; P:intracellular signaling cascade; IEA.
DR GO; GO:0006468; P:protein amino acid phosphorylation; IEA.
DR InterPro; IPR008973; C2_CaLb.
DR InterPro; IPR000345; CytC_heme_BS.
DR InterPro; IPR002219; DAG_Pe-bind.
DR InterPro; IPR000719; Prot_kinase.
DR InterPro; IPR002250; Ser_Thr_kinase.
DR InterPro; IPR008271; Ser_Thr_kinase.
DR InterPro; IPR001245; Tyr_kinase.
DR Pfam; PF00130; DAG_Pe-bind; 2.

GenCore version 5.1.6
Copyright (c) 1993 - 2004 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: March 25, 2004, 23:31:44 ; Search time 140 Seconds

(without alignments)
1307.791 Million cell updates/sec

Title: US-09-805-020-72

Sequence: 1 MSPELRIGLNFDGSCGSC.....LVSEFLVSNLHVANDRY 648

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 1586107 seqs, 282547505 residues

Total number of hits satisfying chosen parameters: 1586107

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%
Listing first 45 summaries

Database : A_Geneseq_29Jan04:*

1: geneseqp1980s:*\n2: geneseqp1990s:*\n3: geneseqp2000s:*\n4: geneseqp2001s:*\n5: geneseqp2002s:*\n6: geneseqp2003as:*\n7: geneseqp2003bs:*\n8: geneseqp2004s:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	3506	100.0	648	5	ABG79705 Tumour in
2	3344	95.4	615	5	ABG79705 Tumour in
3	3337	95.2	706	4	ABG62870 Amino aci
4	3337	95.2	706	6	ABP56907 Human pro
5	3327	94.9	706	6	ABG60648 Human pro
6	3327	94.9	706	6	ABR63656 Human pro
7	2057.5	58.7	673	7	ADE57523 Rat Prote
8	2057.5	58.7	673	7	ADE57525 Rat Prote
9	2037.5	58.1	676	4	AA848037 Human pro
10	1499	42.8	704	3	AA91091 Caenorhab
11	1499	42.8	704	3	AA91091 Caenorhab
12	1343	38.3	567	3	AA959506 C. eleg
13	1343	38.3	567	3	AA959507 C. eleg
14	1298.5	37.0	737	5	AA018490 Nematode
15	1298.5	37.0	737	5	AA018490 Human ins
16	1298.5	37.0	737	7	ADE57469 Human pro
17	1298.5	37.0	737	7	ADE57541 Human pro
18	1298.5	37.0	737	7	ADE57534 Human pro
19	1298.5	37.0	737	7	ADE57533 Human pro
20	1298.5	37.0	737	7	ADE57537 Human pro
21	1296.5	37.0	737	6	ADA50073 Human pro
22	1296.5	37.0	737	6	ADA50073 Mouse pro
23	1290.5	36.8	737	7	AAE39167 Mouse pro
24	1290.5	36.8	737	7	ADE57531 Rat Prote
25	1290.5	36.8	737	7	ADE57532 Rat Prote
					ADE57535 Rat Prote

26	1290.5	36.8	737	7	ADE57539 Rat Prote
27	1290.5	36.8	737	7	ADE57527 Rat Prote
28	1278.5	36.5	739	4	ABE58410 Drosophil
29	1251	35.7	682	5	AA018491 Human ins
30	1241.5	35.4	682	7	ADG37371 Nuclear f
31	1199.5	34.2	522	7	ADG37369 Nuclear f
32	1170	33.4	672	3	AA933259 CDNA enco
33	1170	33.4	672	4	AAE13041 Human pro
34	1170	33.3	681	4	ABG06337 Novel hum
35	1169	33.3	672	2	AA94765 Type III
36	1166	33.3	672	2	AA66726 Protein K
37	1163	33.2	672	7	ADG56843 Human alp
38	1157.5	33.0	671	7	ADG56866 Rat Prote
39	1157.5	33.0	671	7	ADD45358 Rat Prote
40	1157.5	33.0	671	7	ADD45358 Human pro
41	1157.5	33.0	673	6	AA029576 Human PC4
42	1157.5	33.0	673	7	ADG56868 Human pro
43	1157.5	33.0	918	3	AA970784 EGFP-PKCb
44	1155	32.9	672	5	ABE57302 Mouse lsc
45	1155	32.9	916	2	AAW85023 Amino aci

ALIGNMENTS

RESULT 1

ABG79705 standard; protein, 648 AA.

ABG79705;

15-NOV-2002 (first entry)

Tumour involved gene (TIG) splice variant protein, NV-36.

Human; splice variant; tumour-involved gene; TIG;

pharmaceutical composition; cancer; diagnostic; tumour; gene therapy;

endothelial cell; cell differentiation; cell proliferation; apoptosis;

gene therapy.

Hom sapiens.

US2002086384-A1.

13-MAR-2001; 2001US-00805020.

14-MAR-2000; 2000IL-00135402.

16-MAY-2000; 2000IL-00136154.

(LEVI/) LEVINE Z.

(DAVID/) DAVID A.

(ROMA/) ROMANO C.

(BERN/) BERNSTEIN J.

Levine Z, David A, Romano C, Bernstein J;

WPI; 2002-635679/68.

N-PSDB; ABE55235.

Novel nucleic acid sequence, which is an alternative splicing variant of

tumour involved gene, useful for detecting cancer, predisposition to

cancer, for evaluating cancer state and in gene therapy for treating

cancer.

Claim 4; Page 105-107; 180pp; English.

The invention discloses isolated human nucleic acid alternative splicing

variants that are all tumour-involved genes (TIGs). The nucleic acids and

polypeptides are useful for determining the level of a nucleic acid or

polypeptide in a biological sample, for detecting a variant nucleic acid

or polypeptide sequence in a biological sample, for determining the level

CC of variant nucleic acid or polypeptide sequences in a biological sample
 CC and for determining the ratio between the level of variant sequence in a
 CC first biological sample and the level of the original sequence from which
 CC the variant has been varied by alternative splicing in a second
 CC biological sample and for raising antibodies. A pharmaceutical
 CC composition comprising a carrier and the nucleic acid, is useful for
 CC treating diseases (e.g. cancer) that can be ameliorated or cured by
 CC increasing or decreasing the level of the encoded protein. The nucleic
 CC acids are also useful for diagnostic purposes, especially for detecting
 CC cancer or a predisposition to cancer, for evaluating the state or
 CC aggressiveness of cancer disease, in basic research, for understanding
 CC the physiological function of the original TIG, in targeting or
 CC developing pharmaceuticals, for distinguishing various stages in the life
 CC cycle of the same type of cells which may be helpful for the development
 CC of pharmaceuticals for various cancer stages in which cell cycle is non-
 CC normal, for determining mutations in tumour-involved genes and in gene
 CC therapy. The polypeptides are useful for identifying compounds capable of
 CC binding to the variant product and modulating its activity and for
 CC modulating endothelial differentiation and proliferation, as well as to
 CC modulate apoptosis either ex vivo or in vivo. The sequences presented in
 CC ABG796700-ABG79705 are the new variants (NV) 1-36 proteins of the TIGs
 CC disclosed

XX Sequence 648 AA;

Query Match 100.0%; Score 3506; DB 5; Length 648;
 Best Local Similarity 100.0%; Pred. No. 0;
 Matches 648; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MSPFIRIGLSNPDGSCSCGGEANPFCATLYKVEYSENGQVITCKPMTYPPMSTF 60
 DB 1 MSPFIRIGLSNPDGSCSCGGEANPFCATLYKVEYSENGQVITCKPMTYPPMSTF 60
 QY 61 DAHINKGRVMQIIVKGNVDLISSETTVLSELAERCGRNKKETIMLELKQGMNAR 120
 DB 61 DAHINKGRVMQIIVKGNVDLISSETTVLSELAERCGRNKKETIMLELKQGMNAR 120
 QY 121 YFLKSDTKDNNEFTGEPFALHQRGAIKQAKVHVCHETNTATPPQPCSCVCEPV 180
 DB 121 YFLKSDTKDNNEFTGEPFALHQRGAIKQAKVHVCHETNTATPPQPCSCVCEPV 180
 QY 121 YFLKSDTKDNNEFTGEPFALHQRGAIKQAKVHVCHETNTATPPQPCSCVCEPV 180
 DB 121 YFLKSDTKDNNEFTGEPFALHQRGAIKQAKVHVCHETNTATPPQPCSCVCEPV 180
 QY 181 WGLNKQGYOCRCQNAIHKKCIDKVIACGSAINSRETMHKKRPKIDMHRKQVNYK 240
 DB 181 WGLNKQGYOCRCQNAIHKKCIDKVIACGSAINSRETMHKKRPKIDMHRKQVNYK 240
 QY 241 SPTFECGCTLWGLARQGLKDCAGMNVHRCTQVANIIGINQKMAELAMIESSTQ 300
 DB 241 SPTFECGCTLWGLARQGLKDCAGMNVHRCTQVANIIGINQKMAELAMIESSTQ 300
 QY 301 ARCLADTQIFREGVEIGLPCSIKNKARPCLPTPGKREPOGISWSPSLDEVKMLP 360
 DB 301 ARCLADTQIFREGVEIGLPCSIKNKARPCLPTPGKREPOGISWSPSLDEVKMLP 360
 QY 361 EPELNKRPSTQIKIKIEDFILHAKMLGKSGFQVLAEPKKTNPFAIKAKKQVVLMD 420
 DB 361 EPELNKRPSTQIKIKIEDFILHAKMLGKSGFQVLAEPKKTNPFAIKAKKQVVLMD 420
 QY 421 DVECTMVKRYTSLAMEHPTLHMECTEOTKENLFFWVEYINGDLMWTHIOSCHKPLSR 480
 DB 421 DVECTMVKRYTSLAMEHPTLHMECTEOTKENLFFWVEYINGDLMWTHIOSCHKPLSR 480
 QY 481 ATFYAAEIIILQFLSHKGIYVRDKLDNILLDKGHIKIADFGMKEMMLGDAKNTFC 540
 DB 481 ATFYAAEIIILQFLSHKGIYVRDKLDNILLDKGHIKIADFGMKEMMLGDAKNTFC 540
 QY 541 GTPDYIAEIIILGQKYNVSVDWMSFGVLYEMLLGQSPFHGQDEELPHSIRMDNPPYR 600
 DB 541 GTPDYIAEIIILGQKYNVSVDWMSFGVLYEMLLGQSPFHGQDEELPHSIRMDNPPYR 600
 QY 601 WLEKAKOLLVKSSEAKSVFIRALGLVSLFLLVSNLNVANDYY 648
 DB 601 WLEKAKOLLVKSSEAKSVFIRALGLVSLFLLVSNLNVANDYY 648

RESULT 2
 ABG79678
 ID ABG79678 standard; protein; 615 AA.
 AC ABG79678;
 XX
 DT 15-NOV-2002 (first entry)
 XX
 DE Tumour involved gene (TIG) splice variant protein, NV-9.
 XX
 KM Human; splice variant; tumour-involved gene; TIG;
 KM pharmaceutical composition; cancer; diagnostic; tumour; gene therapy;
 KM endothelial cell; cell differentiation; cell proliferation; apoptosis;
 KM gene therapy.
 XX
 OS Homo sapiens.
 XX
 PN US2002086384-A1.
 XX
 PD 04-JUL-2002.
 XX
 PF 13-MAR-2001; 2001US-00805020.
 XX
 PR 14-MAR-2000; 2000IL-00135402.
 PR 16-MAY-2000; 2000IL-00136154.
 XX
 PA (LEVY/) LEVINE Z.
 PA (DAVI/) DAVID A.
 PA (ROMA/) ROMANO C.
 PA (BERN/) BERNSTEIN J.
 PI Levine Z, David A, Romano C, Bernstein J;
 DR WPI: 2002-635679/68.
 DR N-PSDB; ABS65208.
 PT Novel nucleic acid sequence, which is an alternative splicing variant of
 PT tumor involved genes, useful for detecting cancer, predisposition to
 PT cancer, for evaluating cancer state and in gene therapy for treating
 PT cancer.
 PS Claim 4; Page 73-75; 180pp; English.
 XX
 CC The invention discloses isolated human nucleic acid alternative splicing
 CC variants that are all tumour-involved genes (TIGs). The nucleic acids and
 CC polypeptides are useful for determining the level of a nucleic acid or
 CC polypeptide in a biological sample, for detecting a variant nucleic acid
 CC or polypeptide sequence in a biological sample, for determining the level
 CC of variant nucleic acid or polypeptide sequences in a biological sample
 CC and for determining the ratio between the level of variant sequence in a
 CC first biological sample and the level of the original sequence from which
 CC the variant has been varied by alternative splicing in a second
 CC biological sample and for raising antibodies. A pharmaceutical
 CC composition comprising a carrier and the nucleic acid, is useful for
 CC treating diseases (e.g. cancer) that can be ameliorated or cured by
 CC increasing or decreasing the level of the encoded protein. The nucleic
 CC acids are also useful for diagnostic purposes, especially for detecting
 CC cancer or a predisposition to cancer, for evaluating the state or
 CC aggressiveness of cancer disease, in basic research, for understanding
 CC the physiological function of the original TIG, in targeting or
 CC developing pharmaceuticals, for distinguishing various stages in the life
 CC cycle of the same type of cells which may be helpful for the development
 CC of pharmaceuticals for various cancer stages in which cell cycle is non-
 CC normal, for determining mutations in tumour-involved genes and in gene
 CC therapy. The polypeptides are useful for identifying compounds capable of
 CC binding to the variant product and modulating its activity and for
 CC modulating endothelial differentiation and proliferation, as well as to
 CC modulate apoptosis either ex vivo or in vivo. The sequences presented in
 CC ABG796700-ABG79705 are the new variants (NV) 1-36 proteins of the TIGs
 CC disclosed
 SQ Sequence 615 AA;

GenCore version 5.1.6
Copyright (c) 1993 - 2004 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: March 25, 2004, 16:38:50 ; Search time 952 Seconds
(without alignments)
10508.935 Million cell updates/sec

Title: US-09-805-020-36

Perfect score: 1 gaattccgcagcccccgcga.....ctccacaacataaaggga 2355

Scoring table: IDENTITY_NUC
Gapop 10.0, Gapext 1.0

Searched: 3373863 seqs, 2124099041 residues

Total number of hits satisfying chosen parameters: 6747726

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%
Listing first 45 summaries

Database :
1: N_Geneseq_29Jan04:*
2: geneseqn1980s:*
3: geneseqn1990s:*
4: geneseqn2000s:*
5: geneseqn2001s:*
6: geneseqn2002s:*
7: geneseqn2003as:*
8: geneseqn2003bs:*
9: geneseqn2003cs:*
10: geneseqn2004s:*

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	2355	100.0	2355	6	ABs65235
2	2331	99.0	2369	6	ABs65208
3	1927.2	81.8	2754	4	AAf59810
4	1927.2	81.8	2754	4	ABf67085
5	1927.2	81.8	2754	8	ACG65477
6	1927.2	81.8	2754	9	ADb84903
7	1857.4	78.9	2705	3	AAa35299
8	1857.4	78.9	2705	3	AAf21421
9	1857.4	78.9	2705	5	AAH42213
10	1857.4	78.9	2705	7	ABz97115
11	1857.4	78.9	2705	7	ABz22924
12	1857.4	78.9	38644	3	AAA35302
13	1857.4	78.9	38644	3	AAf21424
14	1857.4	78.9	38644	7	ABz97118
15	1850.4	78.6	2658	6	AAH42214
16	1836.4	78.0	2121	6	ABV78235
17	1836.4	78.0	2121	6	ABX10054
18	1836.4	78.0	2121	6	ABX10054
19	1836.4	78.0	2121	6	ABX10054
20	685.8	29.1	2909	7	ABT41763
21	685.8	29.1	2909	7	ABT41763
22	685.8	29.1	2909	7	ABT41763
23	682.6	29.0	2891	2	AAQ57016

24	670.2	28.5	2104	3	AAA35290	AAa35290 Human ade
25	670.2	28.5	2104	4	AAf21412	AAf21412 Human low
26	670.2	28.5	2104	4	AAc84222	AAc84222 Human pro
27	670.2	28.5	2104	7	ABz97106	ABz97106 Human nuc
28	664.4	28.2	2031	6	ABV78229	ABV78229 Human PKC
29	664.4	28.2	2031	6	ABz35805	ABz35805 Human PKC
30	664.4	28.2	2031	6	ABX10048	ABX10048 Human PKC
31	664.4	28.2	2031	6	ABL91770	ABL91770 Human pol
32	632.4	26.9	2163	3	AAA35289	AAA35289 Human ade
33	632.4	26.9	2163	3	AAf21411	AAf21411 Human low
34	632.4	26.9	2163	6	ABK83588	ABK83588 Human CDN
35	632.4	26.9	2163	7	ABz97105	ABz97105 Human nuc
36	389	16.5	1423	7	AAa35292	AAa35292 Human ade
37	389	16.5	1423	7	AAf21414	AAf21414 Human low
38	389	16.5	1423	7	ABz97108	ABz97108 Human nuc
39	376	16.0	2274	8	AAQ57014	AAQ57014 PKC eps11
40	374.4	15.9	2274	8	ADA50078	ADA50078 Protein k
41	374.4	15.9	2274	9	AAa35291	AAa35291 Mouse pro
42	374.2	15.9	2244	3	AAa35293	AAa35293 Human ade
43	374.2	15.9	2244	3	AAf21415	AAf21415 Human low
44	374.2	15.9	2244	6	AAf48609	AAf48609 Human ins
45	374.2	15.9	2244	7	ABz97109	ABz97109 Human nuc

ALIGNMENTS

RESULT 1
ABs65235
ID ABs65235 standard; cDNA; 2355 BP.
XX
AC
XX
DT 15-NOV-2002 (first entry)
XX
DE cDNA encoding tumour involved gene (TIG) splice variant, NV-36.
XX
KW Human; ss; gene; splice variant; tumour-involved gene; TIG;
KW pharmaceutical composition; cancer; diagnostic; tumour; gene therapy;
KW endothelial cell; cell differentiation; cell proliferation; apoptosis;
KW gene therapy.
OS Homo sapiens.
XX
PN US2002086384-A1.
XX
PD 04-JUL-2002.
XX
PF 13-MAR-2001; 2001US-00805020.
XX
PR 14-MAR-2000; 2000IL-00135402.
PR 16-MAY-2000; 2000IL-00136154.
XX
PA (LEVI/) LEVINE Z.
PA (DAVI/) DAVID A.
PA (ROMA/) ROMANO C.
PA (BERN/) BERNSTEIN J.
XX
PI Levine Z, David A, Romano C, Bernstein J;
XX
WP1, 2002-635679/68.
DR P-PSDB; ABG79705.
XX
PT novel nucleic acid sequence, which is an alternative splicing variant of
PT tumor involved genes, useful for detecting cancer; predisposition to
PT cancer; for evaluating cancer state and in gene therapy for treating
PT cancer.
XX
PS Claim 1, Page 64-65; 180pp; English.
CC The invention discloses isolated human nucleic acid alternative splicing
CC variants that are all tumour-involved genes (TIGs). The nucleic acids and
CC polypeptides are useful for determining the level of a nucleic acid or

CC polypeptide in a biological sample, for detecting a variant nucleic acid
 CC or polypeptide sequence in a biological sample, for determining the level
 CC of variant nucleic acid or polypeptide sequences in a biological sample
 CC and for determining the ratio between the level of variant sequence in a
 CC first biological sample and the level of the original sequence from which
 CC the variant has been varied by alternative splicing in a second
 CC biological sample and for raising antibodies. A pharmaceutical
 CC composition comprising a carrier and the nucleic acid, is useful for
 CC treating diseases (e.g. cancer) that can be ameliorated or cured by
 CC increasing or decreasing the level of the encoded protein. The nucleic
 CC acids are also useful for diagnostic purposes, especially for detecting
 CC cancer or a predisposition to cancer, for evaluating the state or
 CC aggressiveness of cancer disease, in basic research, for understanding
 CC the physiological function of the original TIG, in targeting or
 CC developing pharmaceuticals, for distinguishing various stages in the life
 CC cycle of the same type of cells which may be helpful for the development
 CC of pharmaceuticals for various cancer stages in which cell cycle is non-
 CC normal, for determining mutations in tumour-involved genes and in gene
 CC therapy. The polypeptides are useful for identifying compounds capable of
 CC binding to the variant product and modulating its activity and for
 CC modulating endothelial differentiation and proliferation, as well as to
 CC modulate apoptosis either ex vivo or in vivo. The sequences presented in
 CC AB5652200-AB565235 are the coding sequences for the new variants (NV) 1-
 CC 36 of the TIGs disclosed

SQ Sequence 2355 BP; 667 A; 537 C; 594 G; 557 T; 0 U; 0 Other;

Query Match 100.0%; Score 2355; DB 6; Length 2355;
 Best Local Similarity 100.0%; Pred. No. 0;
 Matches 2355; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GAATTCGCCGACGCCGCGCAATGCCGCGAGTCCCGCGAGTCCCGAGCGCCACCGCGGC 60
 DB 1 GAATTCGCCGACGCCGCGCAATGCCGCGAGTCCCGCGAGTCCCGAGCGCCACCGCGGC 60
 QY AGCAGCGCGCGCGTCTGCTCCAGGCGGCAACCAATGCGCATTTCTTGAGATTGAGCTT 120
 DB AGCAGCGCGCGCGTCTGCTCCAGGCGGCAACCAATGCGCATTTCTTGAGATTGAGCTT 120
 QY 61 AGCAGCGCGCGCGTCTGCTCCAGGCGGCAACCAATGCGCATTTCTTGAGATTGAGCTT 120
 DB 61 AGCAGCGCGCGCGTCTGCTCCAGGCGGCAACCAATGCGCATTTCTTGAGATTGAGCTT 120
 QY 121 GTCCCACTTTGACTGCGGCGTCTGCGCAATGCGCGGCGGCGGCGGCGGCGGCGGCGG 180
 DB 121 GTCCCACTTTGACTGCGGCGTCTGCGCAATGCGCGGCGGCGGCGGCGGCGGCGGCGG 180
 QY 181 TGCTGTGCTCGTCAAGAGTATGTGATCAGAGAGCGGAGATGATATCCAGAAA 240
 DB 181 TGCTGTGCTCGTCAAGAGTATGTGATCAGAGAGCGGAGATGATATCCAGAAA 240
 QY 241 GCTTACATGTAACCAACCTTGGAGACAGCATTTTATGCCATATCAACAGGAGAGT 300
 DB 241 GCTTACATGTAACCAACCTTGGAGACAGCATTTTATGCCATATCAACAGGAGAGT 300
 QY 301 CATGAGATCAATGTGAGAGGCAAAAAGTGGACCTCATCTGAAAACCAACCGTGGAGT 360
 DB 301 CATGAGATCAATGTGAGAGGCAAAAAGTGGACCTCATCTGAAAACCAACCGTGGAGT 360
 QY 361 CTACTCGTGGCTGAGAGTGCAGAGAGACAGGAGAGAGAGAGAGAGAGAGAGAGT 420
 DB 361 CTACTCGTGGCTGAGAGTGCAGAGAGACAGGAGAGAGAGAGAGAGAGAGAGAGT 420
 QY 421 GAAACCTCAAGGCGCAATGCTAATGATGCAAGATCTTTGTGAATAGAGTGCACAAA 480
 DB 421 GAAACCTCAAGGCGCAATGCTAATGATGCAAGATCTTTGTGAATAGAGTGCACAAA 480
 QY 481 GACATGATGATGATGAGAGCGAAGGCTTTCTTGCTTGATGAGCGCGGAGTGCAT 540
 DB 481 GACATGATGATGATGAGAGCGAAGGCTTTCTTGCTTGATGAGCGCGGAGTGCAT 540
 QY 541 CAAGAGGCAAGAGTGCACAGCTCAAGTGCAGAGTGCACAGTGCACAGTGCACAGTGCAC 600
 DB 541 CAAGAGGCAAGAGTGCACAGCTCAAGTGCAGAGTGCACAGTGCACAGTGCACAGTGCAC 600
 QY 601 GCCCATTTTGTCTGTCTGCGACAGATTTGTCTGGGCGCTGAACAAAGGCGCTACCA 660
 DB 601 GCCCATTTTGTCTGTCTGCGACAGATTTGTCTGGGCGCTGAACAAAGGCGCTACCA 660

DB 601 GCCCATTTTGTCTGTCTGCGACAGATTTGTCTGGGCGCTGAACAAAGGCGCTACCA 660
 QY 661 GTGCCGACATGCAATGACAGCAATTCACAGAGAGTATGTAATGATTAAGCAAGTG 720
 DB 661 GTGCCGACATGCAATGACAGCAATTCACAGAGAGTATGTAATGATTAAGCAAGTG 720
 QY 721 CACAGATAGCATCAATGACGAGAAACATGTTCCACAGAGAGATTCAGAAATGA 780
 DB 721 CACAGATAGCATCAATGACGAGAAACATGTTCCACAGAGAGATTCAGAAATGA 780
 QY 781 CATGCCACAGATTTAAAGTCTACATTAAGAGCCGACCTTCTGTGAACACTGTG 840
 DB 781 CATGCCACAGATTTAAAGTCTACATTAAGAGCCGACCTTCTGTGAACACTGTG 840
 QY 841 GACCCGCTGTGGGAGCTGGCAGCGCAAGACTCAAGTGTGATGATGGATGAATAGT 900
 DB 841 GACCCGCTGTGGGAGCTGGCAGCGCAAGACTCAAGTGTGATGATGGATGAATAGT 900
 QY 901 GCATCATAGATCCAGACAAAGGTGGCAACCTTTGTGGCATMAACAGAGCTAATG 960
 DB 901 GCATCATAGATCCAGACAAAGGTGGCAACCTTTGTGGCATMAACAGAGCTAATG 960
 QY 961 TGAAGGCTGGGCGCATGATGAGAGCACTCAAGGCTGCTGCTTAAGAGATCTGACA 1020
 DB 961 TGAAGGCTGGGCGCATGATGAGAGCACTCAAGGCTGCTGCTTAAGAGATCTGACA 1020
 QY 1021 GATCTTCAGAGAGGCTCGGTTGAATGCTCTCCATGCTCCATCAAAATGAAGCAAG 1080
 DB 1021 GATCTTCAGAGAGGCTCGGTTGAATGCTCTCCATGCTCCATCAAAATGAAGCAAG 1080
 QY 1081 GCGCGCATGTTTACCGACACCGGAGAAAAGAGAGCTCAGGCGCATTTCTGGAGTCTCC 1140
 DB 1081 GCGCGCATGTTTACCGACACCGGAGAAAAGAGAGCTCAGGCGCATTTCTGGAGTCTCC 1140
 QY 1141 GTTGATGAGTGAATGAATGTCATCTTCAGAACTGAACTGAACAAAGAAAGACC 1200
 DB 1141 GTTGATGAGTGAATGAATGTCATCTTCAGAACTGAACTGAACAAAGAAAGACC 1200
 QY 1201 ATCTGCGAGATTAATCTAAATTTGAGATTTTATCTTGCAAAATGTTGGGAAAG 1260
 DB 1201 ATCTGCGAGATTAATCTAAATTTGAGATTTTATCTTGCAAAATGTTGGGAAAG 1260
 QY 1261 AAGTTTGGCAGAGCTTCTGCGAGAAATCAAGAAACCAATCAATTTTGGCAATAAA 1320
 DB 1261 AAGTTTGGCAGAGCTTCTGCGAGAAATCAAGAAACCAATCAATTTTGGCAATAAA 1320
 QY 1321 GGCCTTAAAGAAAGATGCTGCTTATGAGACGATGATGTAAGTGCACAGATGAGAA 1380
 DB 1321 GGCCTTAAAGAAAGATGCTGCTTATGAGACGATGATGTAAGTGCACAGATGAGAA 1380
 QY 1381 GAGAGTCTTCTTGGCTGGAGAGATCGGTTCTGAAGCAATGTTTGTATCA 1440
 DB 1381 GAGAGTCTTCTTGGCTGGAGAGATCGGTTCTGAAGCAATGTTTGTATCA 1440
 QY 1441 GACCAAGGAAAACCTTTTGTATGAGAGTCAACGAGGAGGACTTAATGACCA 1500
 DB 1441 GACCAAGGAAAACCTTTTGTATGAGAGTCAACGAGGAGGACTTAATGACCA 1500
 QY 1501 CATCCAAAGCTGCGCAAGTGGACCTTCCAGAGCGAGGCTTTATGCTGCGGAATCAT 1560
 DB 1501 CATCCAAAGCTGCGCAAGTGGACCTTCCAGAGCGAGGCTTTATGCTGCGGAATCAT 1560
 QY 1561 TCTTGTGTGACGATCTTCAATCCAAAGAAATGCTCAACAGGAGCTGAAGTGAATPA 1620
 DB 1561 TCTTGTGTGACGATCTTCAATCCAAAGAAATGCTCAACAGGAGCTGAAGTGAATPA 1620
 QY 1621 CATCCGTGTAAGCAAGATGAGCATATCAAGATGCGGATTTTGAATGTGCAAGAGAA 1680
 DB 1621 CATCCGTGTAAGCAAGATGAGCATATCAAGATGCGGATTTTGAATGTGCAAGAGAA 1680
 QY 1681 CATGTTAGAGATGCAAGACGAAATACCTTGTGAGGACACTGACTACATGCCCCAGA 1740
 DB 1681 CATGTTAGAGATGCAAGACGAAATACCTTGTGAGGACACTGACTACATGCCCCAGA 1740

